Randomised, Double-Blind, Parallel, Placebo-Controlled Study of Oral Glucosamine, Methylsulfonylmethane and their Combination in Osteoarthritis

Abstract

Objective: Glucosamine, classified as a slow-acting drug in osteoarthritis (SADOA), is an efficacious chondroprotective agent. Methylsulfonylmethane (MSM), the isoxidised form of dimethyl-sulfoxide (DSMO), is an effective natural analgesic and anti-inflammatory agent. The aim of this study was to compare the efficacy and safety of oral glucosamine (Glu), methylsulfonylmethane (MSM), their combination and placebo in osteoarthritis of the knee.

Patients and design: A total of 118 patients of either sex with mild to moderate osteoarthritis were included in the study and randomised to receive either Glu 500mg, MSM 500mg, Glu and MSM or placebo capsules three times daily for 12 weeks. Patients were evaluated at 0 (before drug administration), 2, 4, 8 and 12 weeks post-treatment for efficacy and safety. The efficacy parameters studied were the pain index, the swelling index, visual analogue scale pain intensity, 15m walking time, the Lequesne index, and consumption of rescue medicine.

Results: Glu, MSM and their combination significantly improved signs and symptoms of osteoarthritis compared with placebo. There was a statistically significant decrease in mean (± SD) pain index from 1.74 ± 0.47 at baseline to 0.65 ± 0.71 at week 12 with Glu (p < 0.001). MSM significantly decreased the mean pain index from 1.53 ± 0.51 to 0.74 ± 0.65, and combination treatment resulted in a more significant decrease in the mean pain index (1.7 ± 0.47 to 0.36 ± 0.33; p < 0.001). After 12 weeks, the mean swelling index significantly decreased with Glu and MSM, while the decrease in swelling index with combination therapy was greater (1.43 ± 0.63 to 0.14 ± 0.35; p < 0.05) after 12 weeks. The combination produced a statistically significant decrease in the Lequesne index. All treatments were well tolerated.

Conclusion: Glu, MSM and their combination produced an analgesic and anti-inflammatory effect in osteoarthritis. Combination therapy showed better efficacy in reducing pain and swelling and in improving the functional ability of joints than the individual agents. All the treatments were well tolerated. The onset of analgesic and anti-inflammatory activity was found to be more rapid with the combination than with Glu. It can be concluded that the combination of MSM with Glu provides better and more rapid improvement in patients with osteoarthritis.

This is a preview of subscription content, log in to check access.

Table I
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. 1.

    Da Camara CC, Dowless GV. Glucosamine sulphate for osteoarthritis. Ann Pharmacother 1998; 32: 580–7

    PubMed  Article  Google Scholar 

  2. 2.

    Setnikar I. Antireactive properties of ‘chondroprotective’ drugs. Int J Tissue React 1992; 14: 253–61

    PubMed  CAS  Google Scholar 

  3. 3.

    Noack W, Fischer M, Firster K, et al. Glucosamine sulphate in osteoarthritis of the knee. Osteoarthritis and cartilage 1994; 2: 51–9

    PubMed  Article  CAS  Google Scholar 

  4. 4.

    Reichelt A, Forster KK, Fischer M, et al. Efficacy and safety of intramuscular glucosamine sulphate in osteoarthritis of the knee. Arzeimittel Forschung 1994; 44(1): 75–80

    CAS  Google Scholar 

  5. 5.

    Lawrence RM. Methysulfonylmethane (MSM): a double-blind study of its use in degerative arthritis. Int J Anti-Aging Med 1998; 1(1): 50

    Google Scholar 

  6. 6.

    Jimenez RAH, Willkens RF. Dimethyl sulfoxide: a perspective of its use in rheumatic diseases. J Lab Clin Med 1982; 100: 489–500

    PubMed  CAS  Google Scholar 

  7. 7.

    Murav’ev Iu V, Venikova MS, Pleskovskaia GN, Riazantseva TA, Sigidin Ia A. Effect of dimethyl sulfoxide and dimethyl sulfone on a destructive process in the joints of mice with spontaneous arthritis. Patol Fiziol Eksp Ter 1991 Mar–Apr; 2: 37–9

    PubMed  Google Scholar 

  8. 8.

    Jacob SW, Herschler R. Dimethyl sulfoxide after twenty years. Ann N Y Acad sci 1983; 411: 13–7

    Article  Google Scholar 

  9. 9.

    Fox RB, Fox WK. Dimethyl sulfoxide prevents hydroxyl radical-mediated depolymerization of hyaluronic acid. Ann N Y Acad sci 1983; 411: 14–8

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Evans MS, Reid KH, Sharp Jr JB. Dimethylsulfoxide (DSMO) blocks conduction in peripheral nerve C fibres: a possible mechanism of analgesia. Neurosci Lett 1993; 150: 145–8

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Zuckner J, Uddin J, Ganter Jr GE. Local application of dimethyl sulfoxide, DMSO combined with triamcinolone acetonide in rheumatoid arthritis. Ann N Y Acad sci 1967; 141: 555–9

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Paulus E. FDA Advisory Committee meeting: methotrexate; guidelines for the clinical evaluation of anti-inflammatory drugs; DMSO in scleroderma. Arthritis Rheum 1986; 29: 1289–90

    PubMed  Article  CAS  Google Scholar 

  13. 13.

    Murav’ev IV, Aliab’eva AP. Use of dimethyl sulfoxide for treating flexion contractures in rheumatoid arthritis patients. Ter Arkh 1984; 56: 128–9

    PubMed  Google Scholar 

  14. 14.

    Hajarizadeh H, Lebredo L, Barrie R, et al. Protective effect of doxorubicin in vitamin C or dimethyl sulfoxide against skin ulceration in the pig. Ann Surg Oncol 1994; 1: 411–4

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Ivannikov AT, Beliaev IK, Altukhova GA, et al. Local application of pentacin in dimethyl sufoxide in skin burns contaminated with 241AM. Vestn Dermatol Venerol 1987; 1: 53–5

    PubMed  Google Scholar 

  16. 16.

    Ozkaya-Bayazit E, Kavak A, Gungor H, et al. Intermittent use of topical dimethyl sulfoxide in macular and popular amyloidosis. Int J Dermatol 1998; 37: 949–54

    PubMed  Article  CAS  Google Scholar 

  17. 17.

    Rizzo R, Grandolfo M, Godeas C, et al. Calcium, sulfur and zinc distribution in normal and arthritic articular equine cartilage: a synchroton radiation-induced X-ray emission (SRIXE) study. J Exp Zool 1995; 273: 82–6

    PubMed  Article  CAS  Google Scholar 

  18. 18.

    Lequesne M, Mery C, Samson M, et al. Indexes of severity for osteo-arthritis of the hip and knee: validation-value in comparison with other assessment tests. Scand J Rheumatol 1982; 22: 2290–6

    Google Scholar 

  19. 19.

    Kellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957; 16: 494–501

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Flaherty SA. Pain measurement tools for clinical practice and research. J Am Assoc Nurse Anesth 1996; 64: 133–9

    CAS  Google Scholar 

  21. 21.

    Flandry F, Hunt JP, Terry GC, et al. Analysis of subjective knee complaints using visual analog scales. Am J Sports Med 1991; 19: 112–8

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 1039–49

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Pujalte JM, Llavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin 1980; 7(2): 110–4

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Lequesne M. Symptomatic slow-acting drugs in osteoarthritis: a novel therapeutic concept? Rev Rheum 1994; 61: 69–73

    Google Scholar 

  25. 25.

    Howell DS, Altman RD. Cartilage repair and conservation in osteoarthritis. Rheum Dis Clin North Am 1993; 19: 713–24

    PubMed  CAS  Google Scholar 

  26. 26.

    Lopez Vaz A. Double blind, clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthritis of the knee in out-patients. Curr Med Res Opin 1982; 8(3): 145–9

    Article  Google Scholar 

  27. 27.

    Rindone JP, Hiller D, Collacott E, et al. Randomized,controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000; 172: 91–4

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Hughes R, Carr A. A randomized, double blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology 2002 Mar; 41(3): 279–84

    PubMed  Article  CAS  Google Scholar 

  29. 29.

    Palmieri L, Conte A, Giovannini L, et al. Metabolic fate of exogenous chondroitin sulphate in the experimental animal. Arzneimittel Forschung 1990; 40: 319–23

    PubMed  CAS  Google Scholar 

  30. 30.

    Conte A, Volpi N, Palmieri L, et al. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulphate. Arzneimittel Forschung 1995; 45: 918–25

    PubMed  CAS  Google Scholar 

  31. 31.

    Morreale P, Manopulo R, Galati M, et al. Comparison of the anti-inflammatory efficacy of chondroitin sulphate and diclofenac sodium in patients with knee osteoarthritis. J Rhem 1996; 214: 1385–91

    Google Scholar 

  32. 32.

    McAlindon TE, La Valley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469–75

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    Moore RD. Diminished inflammatory joint disease in Mrl/1 pr mice ingesting DMSO or MSM [abstract 692]. Proceedings of the Federation of American Societies for Experimental Biology 1985; 510

  34. 34.

    Jacob S. Introductory remarks: MSM after 20 years. Ann N Y Acad Sci 1983; 441: 14–6

    Google Scholar 

  35. 35.

    Parcell S. Sulphur in human nutrition and applications in medicine. Altern Med Rev 2002; 7(1): 22–44

    PubMed  Google Scholar 

  36. 36.

    Jacob SW, Herschler R. Biological actions and medical applications of dimethyl sulfoxide. Ann N Y Acad sci 1983; 411: xiii–vii

    PubMed  Article  CAS  Google Scholar 

  37. 37.

    Perez HD, Elfman F, Marder S. Meclofenamate sodium mono-hydrate inhibits chemotactic factor-induced human polymorphonuclear leukocyte function: a possible explanation for its antiinflammatory effect. Arthritis Rheum 1987 Sep; 30(9): 1023–31

    PubMed  Article  CAS  Google Scholar 

  38. 38.

    Parcell S. Sulfur in human nutrition and applications in medicine. Altern Med Rev 2002 Feb; 7(1): 22–44

    PubMed  Google Scholar 

  39. 39.

    Jimenez RAH, Willkens RF. Dimethyl sulfoxide: a perspective of its use in rheumatic diseases. J Lab Clin Med 1982; 100: 489–500

    PubMed  CAS  Google Scholar 

  40. 40.

    Eberhardt R, Zwingers T, Hofmann R. DMSO in patients with active gonarthrosis: a double-blind placebo controlled phase III study [in German]. Fortschr Med 1995; 113: 446–50

    PubMed  CAS  Google Scholar 

  41. 41.

    Jacob SW, Wood DC. Dimethyl sulfoxide (DMSO): toxicology, pharmacology, and clinical experience. Am J Surg 1967; 114: 414–26

    PubMed  Article  CAS  Google Scholar 

  42. 42.

    Gramajo RJ, Cutroneo EJ, Fernandez DE, et al. A single blind, placebo controlled study of glycosaminoglycan-peptide complex (Rumalon) in patients with osteoarthritis of the hip or knee. Curr Med Res Opin 1989; 11(6): 366–72

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Healers Limited, Chennai, India, for providing a study grant, the research material and the study medication. The authors have no conflicts of interest directly relevant to the content of this study.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dr P. R. Usha.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Usha, P.R., Naidu, M.U.R. Randomised, Double-Blind, Parallel, Placebo-Controlled Study of Oral Glucosamine, Methylsulfonylmethane and their Combination in Osteoarthritis. Clin. Drug Investig. 24, 353–363 (2004). https://doi.org/10.2165/00044011-200424060-00005

Download citation

Keywords

  • Osteoarthritis
  • Chondroitin Sulfate
  • Efficacy Parameter
  • Diary Card
  • Case Record Form